Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Treatment Options for Young "Fit" (FCR Eligible) CLL Pts: Ibrutinib/Rituximab Improve PFS and OS & iFCG Regimen Effective for Pts With IGHV-Mutated CLL
Login to view comments.
Click here to Login
Malignant Hematology